Toksisitas Non Hematologi pada Pasien Kanker Paru Karsinoma Bukan Sel Kecil dengan Pengobatan Epidermal Growth Factor Receptor (EGFR) Tirosin Kinase Inhibitor (TKI) di Kota Medan

Abstract

Background: Epidermal growth factor receptor (EGFR) mutations most commonly occur in non-small cell lung cancer. Tyrosine kinase inhibitors (TKIs) have significant antitumor activity in various cancers with EGFR overexpression, but several studies have reported TKI treatment resistance in lung cancer that is dependent on drug generation. Objective: to determine the non-hematological toxicity of EGFR TKI on life expectancy in non-small cell carcinoma lung cancer (NSCCLC) patients in the city of Medan. Method: This study used a retrospective cross-sectional design. The research was conducted on patients diagnosed with NSCCLC with a positive EGFR mutation and treated with TKI using medical record data at Haji Adam Malik Hospital Medan, Elisabeth Hospital, USU Hospital, and Pirngadi Hospital for the period January 2017-December 2022. Data were analyzed using the Mann-Whitney test. Results: This research obtained 67 patients who were diagnosed with KPKBSK with positive EGFR mutations. 2nd generation TKIs produced lower side effects of skin rash, diarrhea and stomatis than patients who received 1st generation TKIs with a p value < 0.05. 2nd generation TKIs produced greater side effects of paronychia than patients who received 1st generation TKIs with a p value <0.05. Conclusion: EGFR TKI generation 2 has better non-hematological toxicity than TKI generation 1 in KPKBSK.